Marble Harbor Investment Counsel LLC Boosts Stake in Danaher Co. (NYSE:DHR)

Marble Harbor Investment Counsel LLC grew its position in Danaher Co. (NYSE:DHR) by 1.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,402 shares of the conglomerate’s stock after acquiring an additional 270 shares during the quarter. Marble Harbor Investment Counsel LLC’s holdings in Danaher were worth $5,597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after buying an additional 2,998,161 shares during the last quarter. Swedbank AB purchased a new stake in shares of Danaher during the 1st quarter valued at about $676,545,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Danaher by 214.4% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after acquiring an additional 2,096,038 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 0.6 %

Shares of NYSE DHR opened at $274.25 on Monday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $264.55 and a two-hundred day simple moving average of $256.51. The firm has a market cap of $198.07 billion, a PE ratio of 46.48, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.05 earnings per share. Analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DHR shares. Leerink Partners upped their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Robert W. Baird increased their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI dropped their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, TD Cowen increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Insider Buying and Selling

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.